Search research articles
Contact Us
Filters
Showing results (461-470 of 522) with videos related to
Page
of 53
Sort By:
Genes & Development
|
February 27, 2019
BRN2 suppresses apoptosis, reprograms DNA damage repair, and is associated with a high somatic mutation burden in melanoma
Katharine Herbert, Romuald Binet, Jean-Philippe Lambert, et al.
British Journal of Cancer
|
March 16, 2021
Checkpoint-blocker-induced autoimmunity is associated with favourable outcome in metastatic melanoma and distinct T-cell expression profiles
Weiyu Ye, Anna Olsson-Brown, Robert A Watson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 7, 2012
Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumors
Suzanne Leijen, Mark R Middleton, Patricia Tresca, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 6, 2018
Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study
Dejan Juric, Jordi Rodon, Josep Tabernero, et al.
Journal of Clinical Pharmacology
|
December 3, 2014
Assessment of the drug interaction potential and single- and repeat-dose pharmacokinetics of the BRAF inhibitor dabrafenib
A Benjamin Suttle, Kenneth F Grossmann, Daniele Ouellet, et al.
Bioorganic & Medicinal Chemistry Letters
|
February 16, 2007
Inhibitors of HCV NS5B polymerase: synthesis and structure-activity relationships of unsymmetrical 1-hydroxy-4,4-dialkyl-3-oxo-3,4-dihydronaphthalene benzothiadiazine derivatives
A Chris Krueger, Darold L Madigan, Brian E Green, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 21, 2020
Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma
Mark R Middleton, Cheryl McAlpine, Victoria K Woodcock, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 24, 2020
sFRP2 Supersedes VEGF as an Age-related Driver of Angiogenesis in Melanoma, Affecting Response to Anti-VEGF Therapy in Older Patients
Mitchell E Fane, Brett L Ecker, Amanpreet Kaur, et al.
The Lancet. Oncology
|
October 12, 2024
Validity and timeliness of cancer diagnosis data collected during a prospective cohort study and reported by the English and Welsh cancer registries: a retrospective, comparative analysis
Ashley Jackson, Pradeep S Virdee, Sharon Tonner, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 28, 2021
Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006
G V Long, A Arance, L Mortier, et al.
Page
of 53
Search research articles
Search
Showing results (461-470 of 522) with videos related to
Sort By:
Page
of 53
Genes & Development
|
February 27, 2019
BRN2 suppresses apoptosis, reprograms DNA damage repair, and is associated with a high somatic mutation burden in melanoma
Katharine Herbert, Romuald Binet, Jean-Philippe Lambert, et al.
British Journal of Cancer
|
March 16, 2021
Checkpoint-blocker-induced autoimmunity is associated with favourable outcome in metastatic melanoma and distinct T-cell expression profiles
Weiyu Ye, Anna Olsson-Brown, Robert A Watson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 7, 2012
Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumors
Suzanne Leijen, Mark R Middleton, Patricia Tresca, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 6, 2018
Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study
Dejan Juric, Jordi Rodon, Josep Tabernero, et al.
Journal of Clinical Pharmacology
|
December 3, 2014
Assessment of the drug interaction potential and single- and repeat-dose pharmacokinetics of the BRAF inhibitor dabrafenib
A Benjamin Suttle, Kenneth F Grossmann, Daniele Ouellet, et al.
Bioorganic & Medicinal Chemistry Letters
|
February 16, 2007
Inhibitors of HCV NS5B polymerase: synthesis and structure-activity relationships of unsymmetrical 1-hydroxy-4,4-dialkyl-3-oxo-3,4-dihydronaphthalene benzothiadiazine derivatives
A Chris Krueger, Darold L Madigan, Brian E Green, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 21, 2020
Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma
Mark R Middleton, Cheryl McAlpine, Victoria K Woodcock, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 24, 2020
sFRP2 Supersedes VEGF as an Age-related Driver of Angiogenesis in Melanoma, Affecting Response to Anti-VEGF Therapy in Older Patients
Mitchell E Fane, Brett L Ecker, Amanpreet Kaur, et al.
The Lancet. Oncology
|
October 12, 2024
Validity and timeliness of cancer diagnosis data collected during a prospective cohort study and reported by the English and Welsh cancer registries: a retrospective, comparative analysis
Ashley Jackson, Pradeep S Virdee, Sharon Tonner, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 28, 2021
Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006
G V Long, A Arance, L Mortier, et al.
Page
of 53